Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
February 04, 2026 09:35 ET | Source: Adial Pharmaceuticals, Inc GLEN ALLEN,…
Manipal Hospitals Enhances Movement and Confidence Through Awareness on Movement Disorders
BENGALURU, India, Dec. 8, 2025 /PRNewswire/ -- Parkinson's disease often begins far…
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinsons Disease and Movement Disorders
– ARV-102 was well tolerated in clinical trials for both healthy volunteers…
